A PYMNTS Company

US: Genetics testing patent fight plagued by pessimism

By  |  March 11, 2014

Shares for Myriad Genetics took a nosedive as pessimism surrounds the company in its fight against a rival’s alleged infringement on Myriad patents, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The company lost a bid to have its rival’s products blocked while the lawsuit is pending. Myriad is suing Ambry Genetics for allegations the company violated Myriad patents, but US District Judge Robert Shelby said the company is unlikely to emerge successful in the cases.

    Reports say there are “substantial questions,” as the judge put it, as to whether the property in question actually constitute a patent.

    Reports say the genetics company claims Ambry infringed on patents involving tests that detect breast and ovarian cancer.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.